Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 9/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23105313 | 1.00 | NPC1 (0.43) | NPC1RAB9ASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL23105314 | 1.00 | NPC1 (0.43) | NPC1RAB9ASLC6A4SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL23149365 | 0.99 | NPC1 (0.42) | NPC1RAB9ASLC6A4SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL23149362 | 0.99 | NPC1 (0.42) | NPC1RAB9ASLC6A4SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL23149364 | 0.99 | NPC1 (0.42) | NPC1RAB9ASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL26763939 | 0.86 | NPC1 (0.44) | NPC1RAB9ASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL23105351 | 0.86 | NPC1 (0.44) | NPC1RAB9ASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL19834182 | 0.85 | MGLL (0.47) | NPC1RAB9ASLC6A4SLC6A2SLC6A3 | |
| Trifluoroacetic Acid SCHEMBL23091763 | 0.77 | NPC1 (0.45) | NPC1RAB9ASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL19833906 | 0.77 | MGLL (0.50) | NPC1RAB9ASLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4028401-B1 | 4,4A,5,7,8,8A-HEXAPYRIDO[4,3-B][1,4]OXAZIN-3-ONE COMPOUNDS AS MAGL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-11-22 | — | — | EP | disclosed |
| US-20220275005-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-09-01 | — | — | US | disclosed |
| EP-4028401-A1 | 4,4A,5,7,8,8A-HEXAPYRIDO[4,3-B][1,4]OXAZIN-3-ONE COMPOUNDS AS MAGL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2022-07-20 | — | — | EP | disclosed |
| CN-114364682-A | Compound 4,4A,5,7,8, 8A-hexapyrido [4,3-B ] [1,4] oxazin-3-one as MAGL inhibitor | 豪夫迈·罗氏有限公司 | 2022-04-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220275005-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP4B1, CYP4X1 | NPC1 2233/4885RAB9A 1485/4885SLC6A4 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.